Assembly Biosciences, Inc. (NASDAQ: ASMB)

Assembly Biosciences, Inc. is a biotechnology company focused on discovering and developing antiviral therapeutics for serious viral diseases. The company’s pipeline includes long acting helicase primase inhibitors (HPIs) ABI‑1179 and ABI‑5366 for the treatment of recurrent genital herpes caused by HSV 1 and HSV 2, an oral hepatitis delta virus (HDV) entry inhibitor ABI‑6250, a next generation capsid assembly modulator (CAM) ABI‑4334 designed to disrupt hepatitis B virus (HBV) replication, and a broad spectrum non nucleoside polymerase inhibitor (NNPI) ABI‑7272 for transplant associated herpesviruses such as cytomegalovirus, Epstein‑Barr virus, and varicella zoster virus. Each program targets a distinct viral mechanism with the goal of providing effective, durable treatment options where current therapies are limited. As of the end of 2025, the HPI candidates ABI‑1179 and ABI‑5366 have completed Phase 1b trials and are ready to advance to Phase 2 under Gilead’s direction. The HDV entry inhibitor ABI‑6250 has finished Phase 1a studies and is expected to begin Phase 2 in the fourth quarter of 2026. The HBV capsid assembly modulator ABI‑4334 has completed Phase 1b and the company is actively seeking a partner to further develop the program. The broad spectrum NNPI ABI‑7272 is undergoing preclinical studies to enable a regulatory filing for transplant‑associated herpesviruses.

Assembly Biosciences, Inc. generates revenue principally from its collaboration and licensing agreements with Gilead Sciences, Inc. In October 2023 the company received an $84.8 million upfront payment under the collaboration agreement, followed by a $10.0 million payment pursuant to a first amendment to the agreement, and a $35.0 million payment when Gilead exercised its option to license the helicase primase inhibitor program in December 2025. Gilead also made equity investments of $15.2 million in 2023 and additional share purchases in 2024 and 2025. The partnership entitles Assembly Biosciences to future milestone payments that could total up to $330.0 million per program, as well as tiered royalties ranging from the high single digits to the low teens on net sales of any successfully commercialized product. In addition, the company may seek further partnerships or licensing deals for its hepatitis B capsid assembly modulator and other pipeline assets to generate additional revenue streams. The company has not yet recorded any product sales revenue, as all of its candidates remain investigational. Consequently, its financial results are driven primarily by the upfront, milestone, and equity payments received from Gilead, as well as any future licensing or collaboration agreements it may secure.

• no_segments_reported.

Within the antiviral therapeutics industry, Assembly Biosciences, Inc. occupies a niche as a preclinical and clinical stage developer of novel mechanisms targeting hepatitis B, hepatitis delta, and herpesviruses. The company competes with larger pharmaceutical firms such as GlaxoSmithKline plc, Enanta Pharmaceuticals, Inc., Arbutus Biopharma Corporation, and Vir Biotechnology, Inc., as well as specialized biotechs like Mirum Pharmaceuticals, Aligos Therapeutics, and Innovative Molecules. Its competitive advantages stem from a proprietary chemistry platform that yields long acting, high potency molecules with distinct mechanisms of action, and from the strategic partnership with Gilead that provides funding, expertise, and potential pathways to late stage development and commercialization. Additionally, the company’s focus on targets with limited existing therapeutic options, such as the hepatitis delta virus entry inhibitor and the capsid assembly modulator that addresses covalently closed circular DNA, differentiates it from many competitors that rely on nucleos(t)ide analogues. For the hepatitis delta virus entry inhibitor, the primary competitor is the approved peptide bulevirtide, which requires subcutaneous injection, whereas ABI‑6250 aims to offer an oral alternative. In the hepatitis B space, companies such as GlaxoSmithKline, Arbutus Biopharma, and Vir Biotechnology are developing capsid assembly modulators and other novel mechanisms. For genital herpes, the current standard of care relies on nucleoside analogues like acyclovir, valacyclovir, and famciclovir, which have dominated the market for over two decades.

The company’s future customers are patients suffering from chronic hepatitis B, hepatitis delta, recurrent herpes simplex virus infections, and transplant associated herpesviruses, as well as the physicians and healthcare providers who treat these conditions. In the near term, its primary counterpart is Gilead Sciences, Inc., which licenses and develops certain programs, and any future partners that may be secured for the hepatitis B capsid assembly modulator or other pipeline assets. Although no commercial product has been launched yet, the patient populations targeted by its pipeline represent significant unmet medical need, with hundreds of millions of individuals worldwide affected by hepatitis B and hepatitis delta, and millions more experiencing recurrent genital herpes or immunosuppression related viral reactivation after transplantation. According to the World Health Organization, approximately 254 million people live with chronic hepatitis B infection worldwide, and an additional 12 to 72 million of those are also infected with hepatitis delta virus. In the United States and Europe, recurrent genital herpes affects millions of individuals, with an estimated three to five outbreaks per year for many patients. Transplant recipients face a heightened risk of herpesvirus reactivation, with up to 80 percent testing positive for varicella zoster virus and 60 percent for cytomegalovirus, creating a substantial patient base for broad spectrum prophylactic or therapeutic agents.